The epidemiology of microbial agents related to patients with multiple sclerosis (MS) by Navidinia, Masoumeh et al.











 , Khadijeh Gholinejad
1
, Safoura Derakhshan 
2
, Ali Rahimipour 
1
, Faranak Kazerouni 
1
, Mohammad Ali Sahraian
3 
 
1School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
2Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran 
3MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran 
 
*Corresponding Author: email address: dr.navidinia@sbmu.ac.ir (M. Navidinia) 
 
ABSTRACT 
     Multiple Sclerosis (MS) is one of the autoimmune diseases which affects the central nervous system 
and its etiology has not yet been identified. The disparity between youth and disability in reproductive 
ages is considered to be of particular importance for this disease and the need for research which 
illuminates various epidemiological, etiologic, clinical and therapeutic angles of multiple sclerosis is 
deeply felt. The purpose of this study is to consider the epidemiology of microbial agents related to 
patients with multiple sclerosis (MS). From 37 patients with multiple sclerosis according to the 
physician examination and McDonald criteria , serum samples were taken. Until testing, serum samples 
were stored in a freezer at -70 ° C. Subsequently, viral and bacterial agents were identified using 
specific primers and PCR method. In this study, the numbers of microbial agents were as the following: 
7 retrovirus associated with MS (MRSV), 17 EBV, 8 HSV6, 11 JC virus, 10 CMV, 8 B19, 14Corona 
virus, 1 Helicobacter pylori, 15 Acinetobacter, 9 Borrelia burgdorferi, and 19 Chlamydia pneumonia. 
Identification of the relationship between different infectious agents in MS is necessary to prepare 
feasible data about tracing and treatment of MS related to these microorganisms that may be beneficial 
to clinicians to select a convenient empirical therapeutic diet in MS related to pathogens at the bedhead 
and can open up a new path to new therapeutic approaches. 
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INTRODUCTION 
     Multiple sclerosis (MS) is a chronic immune-
mediated inflammatory disease of the central 
nervous system, (CNS) characterized 
pathologically by perivascular infiltrates of 
mononuclear cells, demyelination, axonal loss 
and gliosis with the formation of multiple 
plaques in the brain and spinal cord, and 
clinically by a variety of neurological signs and 
symptoms disseminated in time and space [1] . It 
is the second most common cause of 
neurological disability in young adults after 
trauma [2-4]. 
Recent advances in understanding the etiology 
and pathogenesis of MS has contributed to better 
diagnosis and a plethora of therapies which 
substantially affect disease activity and may 
have a long-term impact on the course and 
prognosis of MS. The routine use of magnetic 
resonance imaging (MRI) as a diagnostic tool 
and a surrogate measure, the recognition of the 
need for early diagnosis and treatment of MS 
and the identification of clinical and imaging 
prognostic factors has resulted in several 
revisions of the diagnostic criteria for MS, 
aiming at as early and accurate as possible 
diagnosis of this weighty disease. MS affects 
mainly young people with onset usually at the 
age of 20–50 and a mean age of onset of 30, 
although the disease may develop also in 
childhood and after the age of 60, and is 3 times 
more common in females than in males. The 
cause of MS is still unknown. However, genetic, 
environmental and immunological factors have 
been implicated in the etiology of the disease. 
The total number of people living with MS 
worldwide is estimated to be 2.5 million, 
unevenly distributed throughout the world [1]. 




The prevalence of MS varies geographically. 
Areas of higher prevalence (60 cases per 
100,000 people) include Europe, Russia, 
southern Canada, northern United States, New 
Zealand, and southeast Australia. In the United 
States, the prevalence is estimated to be 100 
cases per 100,000 people [2]. Presentation of 
symptoms in MS usually begins between ages 
20 and 40. When a patient is diagnosed with MS 
after the age of 50, the diagnosis is termed late-
onset multiple sclerosis (LOMS). MS typically 
affects women more than men. In addition, it is 
more commonly seen in Caucasians of Northern 
European decent as compared with other ethnic 
groups, including African-Americans, Asians, 
and Hispanics/ Latinos. However, a recent study 
found that the risk of developing MS was higher 
in African-American women when compared 
with Caucasian American women and men [5]. 
Globally, the median estimated prevalence of 
MS is 112.0 per 100000 and the median 
estimated incidence of MS is 5.2 per 100000. 
Greatest prevalence observed in North America 
and Europe (140 and 108 per 100000, 
respectively). Iran is considered as a country 
with high MS prevalence (51.52 per 100000) in 
Middle East [6-8]. The prevalence of MS 
follows a latitudinal gradient in an incomplete 
distribution model, and varies from less than 
5/100,000 in low-risk areas (e.g. most of Africa 
and Eastern Asia), to more than 100/100,000 in 
high-risk areas (e.g. northern and central Europe, 
North America and Southeastern Australia). 
Migration studies indicate that immigrants tend 
to develop a prevalence rate similar to that of the 
indigenous population, especially if they have 
migrated before puberty. Additionally, several 
clusters and ―epidemics‖ of MS have been 
reported. Taken together, these observations 
support environmental factors in the etiology of 
MS, the most plausible ones being exposure to 
the Epstein–Barr virus (EBV) after early 
childhood and manifestations of infectious 
mononucleosis, reduced exposure to sunlight 
and ultraviolet radiation, vitamin D deficiency 
and cigarette smoking . Recent studies also 
suggest a role for dietary sodium in inducing 
pathogenic Th17 cells which may partially 
account for the observed worldwide increase in 
MS incidence. A wide variety of other 
environmental factors have also been suggested 
as triggers for MS, but their role is disputed [9-
13].Overall prevalence of familial MS in Iran 
was estimated as of 11.4% [95% confidence 
interval (CI): 8.7-14.1]. Point prevalence varied 
between 3.3% and 26.7%. The familial 
prevalence of MS among Iranian people is 
relatively high. More studies are warranted to 
investigate the effect of familial history as a risk 
factor for MS [14]. Previously, Iran was 
considered a low prevalence area, but recent 
investigations have shown that the prevalence of 
MS in Iran has increased significantly  [15]. 
This increasing pattern in the rate of MS may 
have several causes; however, changes in 
lifestyle and new and advanced diagnostic 
methods are regarded as the most important 
causes. Unfortunately, Iran does not have a 
national registry for patients with MS. 
Nevertheless, there is a national computerized 
registration system which holds the information 
of every patient with MS in the country who has 
registered and received beta interferon 
medication from the Ministry of Health and 
Medical Education (MOHME). The Iranian 
government covers a considerable percentage of 
the treatment costs for patients with MS 
receiving beta interferon according to this 
registry. Although studying the data on this 
group of patients does not yield precise and 
comprehensive information on all patients with 
MS in Iran, even an evaluation of these data 
demonstrates that the prevalence rate has 
increased significantly. In December 2011, the 
Iranian MOHME registry listed 34,605 MS 
patients in Iran. Seventy-seven percent were 
women. Given that Iran’s population in 2011 
was 75,600,000, the prevalence rate of MS was 
calculated as 45/100,000 of population [2]. 
Seventy percent of these patients were between 
20-40 years of age. The maximum prevalence 
rate (80 per 100,000 populations) was seen in 
Isfahan province, located in the central part of 
Iran. The minimum prevalence rate (6 per 
100,000 populations) was seen in Sistan-
Baluchestan province, located in the southeast 
part of Iran. This province has a warm and dry 
climate[2] . Other environmental factors, such as 
smoking or viral and bacterial infections, have 
been shown to increase the risk of developing 
MS. So, in this study, the role of microbial 
agents in MS etiology and pathogenesis was 
studied. 
  
MATERIALS AND METHODS 
Patients  




     Thirty seven patients with multiple sclerosis 
were included in this study. The McDonald 
criteria was first established in 2001 as a 
standard  means of diagnosing multiple sclerosis 
(MS) with sensitivity and speed by neurologist 
Ian McDonald  and a  team of researchers . (It is 
also known as the International Panel on MS 
Diagnosis, and the original and subsequent 
panels were, at least in part, organized by the 
National Multiple Sclerosis Society). The 
McDonald Criteria is distinguished by 
incorporating clinical evaluation with magnetic 
resonance imaging (MRI) scans in establishing 
MS. Nonetheless, like an earlier approach, it too 
requires: Evidence of damage to the central 
nervous system (CNS; the brain, spinal cord and 
optic nerves) that is ―disseminated in time,‖ 
meaning damage that occurs on different dates; 
Evidence of damage ―disseminated in space,‖ or 
found on two or more parts of the CNS. A 2010 
revision to the McDonald Criteria (which 
followed a 2005 update) reflected better 
understanding of MS and improved MRI 
techniques and made possible a faster diagnosis 
— one that is, for a first time, potentially based 
on only one demyelinating relapse or 
attack provided certain criteria are met. These 
new criteria are dissemination in time, if two 
lesions are evident at a first attack and 
dissemination in both time and space if only one 
lesion is evident. This change was a key one 
because of the importance of moving patients 
with confirmed disease quickly onto disease-
modifying therapies that may slow disease 
progression [16]. 
PCR conditions  
     The bacterial and viral genomic extraction 
was carried out using an extraction kit according 
to the manufacturer's protocol. The genes were 
then identified by PCR method. The sequences 
of primers HSV, EBV, JC virus, Retrovirus, 
B19, Chlamydia pneumonia, Borrelia 
burgdorferi and Helicobacter pylori were 
checked for nucleotide sequencing in the Gene  
Bank blast. By AccuPrep Genomic DNA 
extraction kit (cat.no.k-3032 lot no.1008J, 
BIONEER), DNA was extracted from all 
samples. PCR amplification profile comprised of 
a 300 nM concentration of each specific primer 
(Eurofins MWG Operon); 200 mM (each) 
deoxynucleoside triphosphates dCTP, dGTP, 
dATP, and dUTP; 0.125 U of Taq DNA 
polymerase; and 5.5 mM MgCl2 (from GENET 
BIO, prime Taq TM DNA  
polymerase,URL:www.genetbio.com). The PCR 
products were analyzed by gel electrophoresis 
on 1.5% BIONEER agarose     gels in    1X TBE  
buffer (890 mM of boric acid,      890    mMTris,  
40ml of 0.5 M EDTA, pH 8.0) at 100 V for 60 
min. Green loading buffer with DNA stain (Jena 
Bioscience, Lot: 111.034) was used during 
loading the samples and ladder. The sizes of the 
PCR products were determined by comparison 
with the molecular size standard (50bp-1Kb 
linear scale); low range DNA ladder or 100bp-
3Kb linear scale and mid-range DNA ladder, 
Jena Bioscience. All control strains and primer 
sequences were as described previously [17-24].  
 
STATISTICS 
     Data analysis is performed using SPSS 
software version 22. 
 
RESULTS 
     In this study, the numbers of microbial agents 
were as follows: 7 Retrovirus associated with 
MS (MRSV), 17 EBV, 8 HSV6, 11 JC, 10 
CMV, 8 B19, 14 Corona virus, 1 Helicobacter 
pylori, 15 Acinetobacter, 9 Borrelia burgdorferi, 
and 19 Chlamydia pneumonia. Based on figure 
1, EBV virus was the highest and MRSV was 
the lowest in patients with MS. Based on figure 
2 Chlamydia pneumonia was the highest and 
Helicobacter pylori was the lowest in patients 
with MS. 





Figure 1. The numbers of viral agents were detected in patients with MS 
 
Figure 2. The numbers of bacterial agents were detected in patients with MS 
 
DISCUSSION 
     MS disease is the most common cause of 
disability in young people. Until now, 
definitive treatment of this disease is not 
possible, but existing drugs can reduce the 
number of attacks and, as a result, disability 
due to the disease. More than 2 million people 
in the world suffer from the disease, and each 
patient's social and therapeutic cost is $ 2.4 
million. There is no accurate data on the 
disease and exact number of patients with MS 
has not been reported, but it seems that more 
than 40,000 people in our country suffer from 
the disease, most being young women. The 
disease has different steps in the affected 
population, as there are no signs and symptoms 
in some patients, but some of them suffer from 
significant disability in a short period of time. 
The prevalence of this disease in the world is 
increasing, with Iran being a part of it, but 
since the epidemiology of this disease in the 
country has not been made, the record is not 
precise [25]. According to a study done by 
Ramroodi N and et al, 74.2% of the case group 
(from 31 patients) and 2.34% of the control 
group (60 healthy individuals) were positive for 
antibodies antiviral HHV- 6. The presence of 
anti-HHV-6 was more than 5 times in control 
group. Indeed, based on this study, the human 
infection with HHV- 6 can be a factor in 
multiple sclerosis[26]. In 2013, a study by 
Mohebbi et al. was conducted to investigate the 
effect of Helicobacter pylori infection on MS. 
In this study, 163 patients with MS were 
enrolled in the study, with a mean age of 32 
years with a standard deviation of 8 years. In 
the control group, 150 patients were studied in 
110 (73%) and 40 (27%) positive tests. 
Negative tests were completed in two groups of 
patients and controls for the amount of 
Helicobacter pylori infection. Based on the 
results of this study, infection with 
Helicobacter pylori is a protective factor 
against MS and the infection can reduce the 
amount of disability and brain damage [27].In a 
study of 26 MS patients in England, antibodies 
against 5 strains of Acinetobacter strain were 
measured by ELISA technique. In this study, 
20 patients were with cerebrovascular accidents 
and 25 healthy subjects were included. The 
study showed that the levels of IgA, IgG and 
IgM antibodies in patients with MS were 
significantly higher than the other two groups. 
Among the five strains studied of 
Acinetobacter  strains, Acinetobacter citacurus, 
Acinetobacter luffyia, had the highest antibody 
titer, so that the level of antibodies synthesized 
was higher than 1: 6400 [28]. In the 
seroepidemiological studies conducted by 
Chemielewska-Badora et al., 10 out of 26 
(38%) patients with MS had antibodies to 
Borlia borgdorferrii, while the result was only 




149 out of 743 tons (20 %) of the patients with 
other neurological diseases (P = 0.042)[29] . In 
another study by Friedman et al., to understand 
the association between the virus and MS, the 
high IgG antibody titer synthesized against 
HHV-6 virus was seen in 21 out of 25 (80%) 
patients with MS while this high-titer was seen 
in only 3 out of 14 patients with other 
autoimmune diseases[30] . Wandinger K and 
ital., reported in their study that all patients 
with MS had anti-EBV antibodies, while only 
86-95% of the control group had this 
characteristic. It was unknown whether the 
infection is a necessary condition for the 
development of MS or not. 
In a study of 37 patients with MS who received 
cyclosporine, JC DNA was detected in urine 
samples of 30 (81%) patients by PCR 
technique. It was necessary to note that this 
virus was also present in 40% of the population 
in the urine. Genomic DNA of the JC virus in 
the cerebrospinal fluid was detected in 9% of 
patients with MS. DNA of the virus in  none of 
the patients with other neurological diseases as  
well as the control group have been identified 
[31-33]. In another study by Stewart et al., 
which included 11 MS patients, 6 patients with 
other neurological diseases and 5 healthy 
subjects, coronavirus 229E was detected in 4 
MS patients. However, in the other two groups 
no cases were found [34].  
Anti-PVB19 antibodies from the IgG class 
were found in patients. The PCR was also used 
to detect the virus DNA in the cerebrospinal 
fluid of the patients was negative [35]. A 
further study by Garcia- Montojo et al. in 2012 
was conducted to investigate the relationship 
between MSRV and gender differences in 
clinical status in MS patients and control group. 
178 patients (62.9% female) and 124 controls 
(56.5% female) were enrolled in this study. 
MSRV was higher in patients with MS than in 
the control group. Women with MS had more 
MSRV load than control women (p = 0.009) 
and had more load in men than controls (p = 
2.77-6). In addition, women had a higher level 
of viral infection than patients (p = 0.007) and 
control group (p = 1.24e-6) [36]. In 2010, 
Handel and his colleagues conducted a meta-
analysis to determine the risk of MS after 
infectious mononucleosis. In a study of 18 
researches, 19390 MS patients and 16007 
controls were examined. This study showed 
that the risk of MS with a high power 
associated with infectious mononucleosis [37]. 
Another study by Sandelle et al., in 2011 
investigated the prevalence of CMV and its 
role in general immunoglobulin pattern among 
Iranian patients with different MS subtypes. In 
this study, serum plasma, saliva and urine 
samples were collected from MS patients and 
healthy subjects. The presence of anti-CMV 
antibodies and anti-CMV-DNA antibodies in 
the samples were evaluated by nephlometric 
and PCR methods. The results showed an 
increase in anti-CMV-DNA antibodies in 
patients as compared to the control group 
(P˂0.001). In addition, systemic CMV 
infection was found in 25.5% of patients (P˂0. 
001). There was a high difference in IgG 
antibody titers against CMV-DNA and total 
IgE in patients and controls [38]. In 2001, a 
study was conducted by Hughes LE et.al in 
which anti-Acinetobacter and Pseudomonas 
aeruginosa antibody responses were evaluated 
in MS patients. The study indicated that there 
was a similarity or molecular imitation between 
Acinetobacter antigens and human antigens 
could be a reason for the increased levels of 
antibodies against this bacterium in MS 
patients other than autoantibodies. Antibodies 
against 5 species of Acinetobacter, 
Pseudomonas aeruginosa and Escherichia coli 
were measured in 26 patients with MS. 
Significant increase in the IgA and IgG levels 
was observed for at least 3 Acinetobacter 
species in the MS patients compared to control 
group (P˂0 . 0001) [28].In studies conducted 
on MS patients, Chlamydia pneumoniae was 
found to be significantly higher in CSF in MS 
patients than in the control group. In addition, a 
large percentage of MS patients had high levels 
of specific antibodies to Chlamydia 
pneumoniae antigens in their CSF as compared 
to the control group [39]. In another meta-
analysis from 26 studies which investigated the 
association of Chlamydia pneumoniae with 
MS, a significant correlation was found 
between MS and the detection of Chlamydia 
pneumonia DNA in CSF by PCR [40]. 
 
CONCLUSION 
     Considering that the disease of multiple 
sclerosis is increasing in Iran and the main 
causes of this disease are unknown. Recent 
studies have shown that infectious agents play 




an important role in the development and 
development of the disease, the introduction of 
an agent as an agent .Identification of the 
relationship between different infectious agents 
in MS is necessary to prepare feasible data 
about tracing and treatment of MS related to 
these microorganisms that may be beneficial to 
clinicians for the purpose of selecting a 
convenient empirical therapeutic diet in MS 
related to pathogens at the bedhead and can 
open up a new path to new therapeutic 
approaches. 
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